Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Diabetes, Obesity & Metabolism
J JendleLEAD-2 and LEAD-3 Study Groups

Abstract

The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D). These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3). Patients with T2D, aged 18-80 years, body mass index (BMI) < or =40 kg/m(2) (LEAD-2), < or =45 kg/m(2) (LEAD-3) and HbA1c 7.0-11.0% were included. Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3. LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD-2: adipose tissue area and hepatic steatosis were assessed. LEAD-2: fat percentage with liraglutide 1.2 and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05) but not vs. placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo. Liver-...Continue Reading

References

Mar 21, 1998·The Journal of Clinical Investigation·A FlintJ J Holst
Mar 10, 2001·The Journal of Nutrition·N Barzilai, I Gabriely
Jul 30, 2002·The American Journal of Clinical Nutrition·Jaehee KimDympna Gallagher
Nov 25, 2004·Metabolism: Clinical and Experimental·Steven R SmithGeorge A Bray
Feb 18, 2005·Diabetes, Obesity & Metabolism·J R Rodríguez-MoctezumaM J Gutiérrez-Rosas
Aug 4, 2005·Endocrine·Máire E DoyleJosephine M Egan
Aug 27, 2005·Diabetes Care·Harold E Lebovitz, Mary Ann Banerji
Dec 21, 2005·Journal of Computer Assisted Tomography·M Raquel OlivaStuart G Silverman
Dec 24, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiaokun DingFrank A Anania
Jan 28, 2006·The Diabetes Educator·Jerry Meece
Feb 4, 2006·The American Journal of Dermatopathology·Philip E Leboit
Mar 15, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C M MackA A Young
Oct 11, 2007·Diabetes, Obesity & Metabolism·David Russell-Jones, Rehman Khan
Nov 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kjeld Hermansen, Lene S Mortensen
Dec 22, 2007·Physiology & Behavior·José R FernándezMardya López-Alarcón
Jan 25, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·S A AmielK Jameson
Jun 3, 2008·Methods in Molecular Biology·Gema Frühbeck
Jun 19, 2008·International Journal of Clinical Practice·N FreemantleS Kumar
Jul 17, 2008·The Journal of Clinical Endocrinology and Metabolism·Chee W Chia, Josephine M Egan
Dec 6, 2008·Diabetes Research and Clinical Practice·Simon R Heller
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group

❮ Previous
Next ❯

Citations

May 15, 2010·Herz·Baptist Gallwitz
Feb 22, 2011·Reviews in Endocrine & Metabolic Disorders·Jenny Tong, Darleen A Sandoval
Jan 9, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J J Holst
Sep 30, 2010·Metabolic Syndrome and Related Disorders·Manuel González-OrtizMaria G Ramos-Zavala
Apr 1, 2011·Diabetes, Obesity & Metabolism·J K DowmanP N Newsome
Oct 15, 2010·International Journal of Clinical Practice. Supplement·J B McGill
Jul 13, 2011·Experimental Diabetes Research·Ilaria DicembriniCarlo Maria Rotella
Oct 5, 2010·Journal of Obesity·Vicky Cheng, Sangeeta R Kashyap
Jun 22, 2013·World Journal of Surgical Oncology·Koji TanakaOsamu Ishikawa
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Lisa M Neff, Robert F Kushner
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Joshua J NeumillerR Keith Campbell
May 18, 2011·Indian Journal of Endocrinology and Metabolism·Mala DharmalingamManash P Baruah
Dec 11, 2013·The Journal of Endocrinology·L van BloemendaalM Diamant
Jun 16, 2012·Indian Journal of Endocrinology and Metabolism·Vishal Gupta
Jan 16, 2014·Diabetology & Metabolic Syndrome·Liselotte FranssonHenrik Ortsäter
Jan 15, 2011·Journal of Endocrinological Investigation·F GiorginoL Laviola
Jan 21, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Miyako Kishimoto, Mitsuhiko Noda
May 9, 2014·Reviews in Endocrine & Metabolic Disorders·Meera Shah, Adrian Vella
Aug 5, 2014·Magnetic Resonance Imaging Clinics of North America·Shane A Wells
Aug 12, 2014·Journal of Endocrinological Investigation·G MuscogiuriA Colao
Sep 10, 2011·Postgraduate Medicine·Thomas Repas
Mar 27, 2012·Journal of Medical Economics·Lesley-Ann MillerDavid Bruhn
Jun 25, 2015·Expert Review of Cardiovascular Therapy·Eva Winning IepsenJens Juul Holst
Mar 7, 2012·Expert Review of Cardiovascular Therapy·Carolyn F Deacon, Nikolaus Marx
Jul 18, 2012·Expert Opinion on Investigational Drugs·Johan JendleZvonko Milicevic
Jan 11, 2016·Aging Clinical and Experimental Research·Simone PernaMariangela Rondanelli
Jul 12, 2011·Clinical Therapeutics·Gina J RyanLynetta Johnson Jobe
Mar 2, 2016·Expert Opinion on Biological Therapy·Thomas Fremming DejgaardSten Madsbad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.